Thematic Take

Powered by

Cyrus Mewawalla, Head of Thematic Intelligence, GlobalData

Foreword: Generative AI as a force of creative destruction

At GlobalData, we define a theme as any issue that keeps a business leader awake at night. Companies are impacted by multiple themes that frequently conflict with one another. What is needed is an effective methodology that reflects, understands, and reconciles these conflicts.   

Our thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. Viewing the world’s data by themes makes it easier to make critical decisions. Companies that invest in the right themes become success stories. Those that miss the essential themes in their industry end up as failures.  

For decades, artificial intelligence (AI) was the domain of university and corporate R&D labs. Recent progress in machine learning (ML) on the back of improved algorithms (e.g., Google’s AlphaGo, OpenAI’s GPT-3) and increasing computing power have enabled AI to solve real-life problems. GlobalData estimates the total AI market will be worth $1 trillion by 2030, up from $103 billion in 2023 at a compound annual growth rate of 39%. In the coming decade, the country that emerges on top in AI will lead the Fourth Industrial Revolution.  

Despite the hype, artificial general intelligence (AGI), or the ability of machines to do anything that a human can and possess consciousness, is still decades away. However, ‘good enough’ AI is already here, capable of human interaction, motion, and decision-making. For example, OpenAI’s ChatGPT can write original prose and chat with human fluency, DeepMind's algorithms can beat the best human chess players, and Boston Dynamics' Atlas robots can somersault. If this evolution continues, it could upend the labor-based capitalist economic model.  

Generative AI is the most talked-about area of AI today. It could drive the next level of business process automation across many industries and cause creative destruction by dismantling old business models while creating new ones. Conversely, it also creates both sustainability and regulatory challenges.

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue